TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the execution of a sponsored research agreement with Michigan State University. These developments mark significant steps in advancing the company's RNA-based therapeutic pipeline focused on treating advanced cancers.
Dr. Moore, who brings extensive expertise in molecular imaging and nanomedicine, will provide strategic guidance on research and development efforts. The company's lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker associated with metastasis. The sponsored research agreement with Michigan State University is expected to support further development of TTX-MC138, including evaluation in combination with other therapies.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA-based treatments for high-risk and advanced cancers. In addition to TTX-MC138, the company has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
For more information on this announcement, visit the full press release here. The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
This news is important as it underscores TransCode's commitment to advancing its RNA-based therapeutic pipeline, potentially offering new treatment options for patients with metastatic cancers. The collaboration with Michigan State University and the appointment of Dr. Moore as SAB Chair could accelerate the development of TTX-MC138 and other candidates, addressing a significant unmet medical need in oncology.
